Location & dates EMBL Heidelberg, Germany 2 - 4 Feb 2017
Deadlines Registration closed Abstract submission closed
organiser_NCT

Topics

  • Unleashing endogenous immunity
  • Clinical studies of T cell-based immunotherapies
  • Markers of effective immune responses
  • Targeting the microenvironment
  • Inducing immunity

Why attend?

The 2017 EMBL-Cancer Core Europe Conference on Cancer Immunotherapy will cover highly relevant sub-disciplines of cancer immunology with a special focus on personalised immunotherapy.

The European Molecular Biology Laboratory (EMBL) and Cancer Core Europe - a consortium of Europe's 6 leading Comprehensive Cancer Centers (Gustave Roussy Cancer Campus Grand Paris, France; Cambridge Cancer Centre, United Kingdom; Karolinska Institutet, Sweden; Netherlands Cancer Institute (NKI), Vall d’Hebron Institute of Oncology, Spain and the German Cancer Research Centre (DKFZ) with it's National Center for Tumour Diseases (NCT) Heidelberg) - are proud to join forces to host the first EMBL-Cancer Core Europe Conference on Cancer Immunotherapy.

Who should attend?

The conference will bring together international basic, translational and clinical scientists and physicians from academics to industry.


This conference is organised in cooperation with DKFZ and NCT Heidelberg.

 

EMBL Courses and Conferences are kindly supported by our Corporate Partnership Programme

Founder partners

  • Leica logo
  • Olympus logo

Corporate partners

  • Becton Dickinson logo
  • Boehringer Ingelheim logo
  • GSK logo
  • Illumina logo
  • Sartorius
  • ThermoFisher logo

Associate partners

  • Eppendorf logo
  • Merck logo
  • Nikon logo
  • Sanofi logo